Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Circulating levels of cell adhesion molecule L1 as a prognostic marker in gastrointestinal stromal tumor patients

Authors: Hilke Zander, Tamina Rawnaq, Max von Wedemeyer, Michael Tachezy, Miriam Kunkel, Gerrit Wolters, Maximilian Bockhorn, Melitta Schachner, Jakob R Izbicki, Jussuf Kaifi

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

L1 cell adhesion molecule (CD171) is expressed in many malignant tumors and its expression correlates with unfavourable outcome. It thus represents a target for tumor diagnosis and therapy. An earlier study conducted by our group identified L1 expression levels in primary gastrointestinal stromal tumors (GIST) as a prognostic marker. The aim of the current study was to compare L1 serum levels of GIST patients with those of healthy controls and to determine whether levels of soluble L1 in sera could serve as a prognostic marker.

Methods

Using a sensitive enzyme-linked immunosorbent assay (ELISA), soluble L1 was measured in sera of 93 GIST patients und 151 healthy controls. Soluble L1 levels were then correlated with clinicopathological data.

Results

Median levels of soluble L1 were significantly higher (p < 0.001; Mann-Whitney U test) in sera of GIST patients compared to healthy individuals. Median soluble L1 levels were particularly elevated in patients with recurrence and relapse (p < 0.05; Mann Whitney U test).

Conclusion

These results suggest that high soluble L1 levels predict poor prognosis and may thus be a promising tumor marker that can contribute to individualise therapy.
Appendix
Available only for authorised users
Literature
1.
Reichardt P, Hogendoorn PC, Tamborini E, Loda M, Gronchi A, Poveda A, Schoffski P: Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. Semin Oncol. 2009, 36 (4): 290-301. 10.1053/j.seminoncol.2009.06.002.CrossRefPubMed
2.
Miettinen M, Majidi M, Lasota J: Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer. 2002, 38 (Suppl 5): S39-51.CrossRefPubMed
3.
Miettinen M, Paal E, Lasota J, Sobin LH: Gastrointestinal glomus tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 32 cases. Am J Surg Pathol. 2002, 26 (3): 301-311. 10.1097/00000478-200203000-00003.CrossRefPubMed
4.
Fletcher CD: Clinicopathologic correlations in gastrointestinal stromal tumors. Hum Pathol. 2002, 33 (5): 455-10.1053/hupa.2002.124119.CrossRefPubMed
5.
Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol. 2002, 10 (2): 81-89. 10.1177/106689690201000201.CrossRefPubMed
6.
Miettinen M, El-Rifai W, L HLS, Lasota J: Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002, 33 (5): 478-483. 10.1053/hupa.2002.124123.CrossRefPubMed
7.
Demetri GD: Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer. 2002, 38 (Suppl 5): S52-59.CrossRefPubMed
8.
Fletcher CD, Fletcher JA: Testing for KIT (CD117) in gastrointestinal stromal tumors: another HercepTest?. Appl Immunohistochem Mol Morphol. 2002, 10 (3): 197-198. 10.1097/00022744-200209000-00001.PubMed
9.
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002, 347 (7): 472-480. 10.1056/NEJMoa020461.CrossRefPubMed
10.
Kaifi JT, Strelow A, Schurr PG, Reichelt U, Yekebas EF, Wachowiak R, Quaas A, Strate T, Schaefer H, Sauter G, Schachner M, Izbicki JR: L1 (CD171) is highly expressed in gastrointestinal stromal tumors. Mod Pathol. 2006, 19 (3): 399-406. 10.1038/modpathol.3800547.CrossRefPubMed
11.
Moos M, Tacke R, Scherer H, Teplow D, Fruh K, Schachner M: Neural adhesion molecule L1 as a member of the immunoglobulin superfamily with binding domains similar to fibronectin. Nature. 1988, 334 (6184): 701-703. 10.1038/334701a0.CrossRefPubMed
12.
Rathjen FG, Schachner M: Immunocytological and biochemical characterization of a new neuronal cell surface component (L1 antigen) which is involved in cell adhesion. EMBO J. 1984, 3 (1): 1-10.PubMedPubMedCentral
13.
Maness PF, Schachner M: Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nat Neurosci. 2007, 10 (1): 19-26. 10.1038/nn1827.CrossRefPubMed
14.
Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Gast D, Joumaa S, Zentgraf H, Fogel M, Altevogt DP: ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. Faseb J. 2003, 17 (2): 292-294.PubMed
15.
Maretzky T, Schulte M, Ludwig A, Rose-John S, Blobel C, Hartmann D, Altevogt P, Saftig P, Reiss K: L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol Cell Biol. 2005, 25 (20): 9040-9053. 10.1128/MCB.25.20.9040-9053.2005.CrossRefPubMedPubMedCentral
16.
Kalus I, Schnegelsberg B, Seidah NG, Kleene R, Schachner M: The proprotein convertase PC5A and a metalloprotease are involved in the proteolytic processing of the neural adhesion molecule L1. J Biol Chem. 2003, 278 (12): 10381-10388. 10.1074/jbc.M208351200.CrossRefPubMed
17.
Lemmon V, Farr KL, Lagenaur C: L1-mediated axon outgrowth occurs via a homophilic binding mechanism. Neuron. 1989, 2 (6): 1597-1603. 10.1016/0896-6273(89)90048-2.CrossRefPubMed
18.
Brummendorf T, Rathjen FG: Axonal glycoproteins with immunoglobulin- and fibronectin type III-related domains in vertebrates: structural features, binding activities, and signal transduction. J Neurochem. 1993, 61 (4): 1207-1219. 10.1111/j.1471-4159.1993.tb13611.x.CrossRefPubMed
19.
Ruppert M, Aigner S, Hubbe M, Yagita H, Altevogt P: The L1 adhesion molecule is a cellular ligand for VLA-5. J Cell Biol. 1995, 131 (6 Pt 2): 1881-1891.CrossRefPubMed
20.
Hillenbrand R, Molthagen M, Montag D, Schachner M: The close homologue of the neural adhesion molecule L1 (CHL1): patterns of expression and promotion of neurite outgrowth by heterophilic interactions. Eur J Neurosci. 1999, 11 (3): 813-826. 10.1046/j.1460-9568.1999.00496.x.CrossRefPubMed
21.
Allory Y, Matsuoka Y, Bazille C, Christensen EI, Ronco P, Debiec H: The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin Cancer Res. 2005, 11 (3): 1190-1197.PubMed
22.
Fogel M, Mechtersheimer S, Huszar M, Smirnov A, Abu-Dahi A, Tilgen W, Reichrath J, Georg T, Altevogt P, Gutwein P: L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Lett. 2003, 189 (2): 237-247. 10.1016/S0304-3835(02)00513-X.CrossRefPubMed
23.
Thies A, Schachner M, Moll I, Berger J, Schulze HJ, Brunner G, Schumacher U: Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer. 2002, 38 (13): 1708-1716. 10.1016/S0959-8049(02)00105-3.CrossRefPubMed
24.
Zecchini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C, Viale G, Liu J, Herlyn M, Godwin AK, Nuciforo PG, Cavallaro U: The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res. 2008, 68 (4): 1110-1118. 10.1158/0008-5472.CAN-07-2897.CrossRefPubMed
25.
Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M, Altevogt P: L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 2003, 362 (9387): 869-875. 10.1016/S0140-6736(03)14342-5.CrossRefPubMed
26.
Bauer S, Yu LK, Demetri GD, Fletcher JA: Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 2006, 66 (18): 9153-9161. 10.1158/0008-5472.CAN-06-0165.CrossRefPubMed
27.
Sommers CL: The role of cadherin-mediated adhesion in breast cancer. J Mammary Gland Biol Neoplasia. 1996, 1 (2): 219-229. 10.1007/BF02013645.CrossRefPubMed
28.
Stoll BA: Biological mechanisms in breast cancer invasiveness: relevance to preventive interventions. Eur J Cancer Prev. 2000, 9 (2): 73-79. 10.1097/00008469-200004000-00002.CrossRefPubMed
29.
Updyke TV, Nicolson GL: Malignant melanoma cell lines selected in vitro for increased homotypic adhesion properties have increased experimental metastatic potential. Clin Exp Metastasis. 1986, 4 (4): 273-284. 10.1007/BF00133592.CrossRefPubMed
30.
Issa Y, Nummer D, Seibel T, Muerkoster SS, Koch M, Schmitz-Winnenthal FH, Galindo L, Weitz J, Beckhove P, Altevogt P: Enhanced L1CAM expression on pancreatic tumor endothelium mediates selective tumor cell transmigration. J Mol Med. 2009, 87 (1): 99-112. 10.1007/s00109-008-0410-7.CrossRefPubMed
31.
Friedli A, Fischer E, Novak-Hofer I, Cohrs S, Ballmer-Hofer K, Schubiger PA, Schibli R, Grunberg J: The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. Int J Biochem Cell Biol. 2009, 41 (7): 1572-1580. 10.1016/j.biocel.2009.01.006.CrossRefPubMed
32.
Mechtersheimer S, Gutwein P, Agmon-Levin N, Stoeck A, Oleszewski M, Riedle S, Postina R, Fahrenholz F, Fogel M, Lemmon V, Altevogt P: Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol. 2001, 155 (4): 661-673. 10.1083/jcb.200101099.CrossRefPubMedPubMedCentral
33.
Stoeck A, Keller S, Riedle S, Sanderson MP, Runz S, Le Naour F, Gutwein P, Ludwig A, Rubinstein E, Altevogt P: A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J. 2006, 393 (Pt 3): 609-618.CrossRefPubMedPubMedCentral
34.
Kaifi JT, Reichelt U, Quaas A, Schurr PG, Wachowiak R, Yekebas EF, Strate T, Schneider C, Pantel K, Schachner M, Sauter G, Izbicki JR: L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol. 2007, 20 (11): 1183-1190. 10.1038/modpathol.3800955.CrossRefPubMed
35.
Gutwein P, Stoeck A, Riedle S, Gast D, Runz S, Condon TP, Marme A, Phong MC, Linderkamp O, Skorokhod A, Altevogt P: Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin Cancer Res. 2005, 11 (7): 2492-2501. 10.1158/1078-0432.CCR-04-1688.CrossRefPubMed
36.
Arlt MJ, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grunberg J, Honer M, Schubiger PA, Altevogt P, Kruger A: Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res. 2006, 66 (2): 936-943. 10.1158/0008-5472.CAN-05-1818.CrossRefPubMed
37.
Nakagawa M, Nabeshima K, Asano S, Hamasaki M, Uesugi N, Tani H, Yamashita Y, Iwasaki H: Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands. Cancer Sci. 2009, 100 (4): 654-662. 10.1111/j.1349-7006.2009.01089.x.CrossRefPubMed
Metadata
Title
Circulating levels of cell adhesion molecule L1 as a prognostic marker in gastrointestinal stromal tumor patients
Authors
Hilke Zander
Tamina Rawnaq
Max von Wedemeyer
Michael Tachezy
Miriam Kunkel
Gerrit Wolters
Maximilian Bockhorn
Melitta Schachner
Jakob R Izbicki
Jussuf Kaifi
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-189

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography

Research article

Detection of antibodies directed at M. hyorhinis p37 in the serum of men with newly diagnosed prostate cancer

Research article

Quality of life assessment as a predictor of survival in non-small cell lung cancer

Research article

The usefulness and feasibility of a screening instrument to identify psychosocial problems in patients receiving curative radiotherapy: a process evaluation

Research article

Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: A tangible union against chemoresistant cancer

Research article

Activating mutation in MET oncogene in familial colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits